Cold Genesys

Cold Genesys is a clinical-stage company focusing on the development of oncolytic viruses and immunotherapies for cancer. In 2010, Cold Genesys acquired the rights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX, now ANIP). A phase I/IIa dose escalating clinical trial has already been completed in 35 patients with nonmuscle invasive bladder cancer (NMIBC). With the promising results from the phase I study, Cold Genesys is currently investigating the company’s first oncolytic virus product, CG0070, in a phase II pivotal, single-arm clinical study with the FDA for NMIBC patients who have failed BCG therapy and refused cystectomy. In addition, Cold Genesys is exploring the use of CG0070 in combination with immune checkpoint modulators (ICMs) in various solid tumors.